Related Experiment Video
Updated: Mar 19, 2026
06:19
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
4.0K
Targeting BET bromodomain proteins in solid tumors.
Vaibhav Sahai1, Amanda J Redig2, Katharine A Collier3
1Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.
Oncotarget
|June 11, 2016
Summary
Bromodomain and extra-terminal (BET) inhibitors show promise in treating various cancers, including solid tumors. This review covers their efficacy, resistance mechanisms, and future potential in oncology.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Increasing interest in bromodomain and extra-terminal (BET) protein inhibitors due to their link to cancer progression.
- Initial efficacy demonstrated in hematologic malignancies, with emerging evidence in solid tumors.
- BET proteins play a critical role in cancer cell proliferation and survival.
Approach:
- Reviewing the efficacy of BET inhibitors in various solid tumors.
- Evaluating the role of BET proteins in acquired resistance to targeted therapies.
- Assessing potential toxicities and resistance mechanisms associated with BET inhibitors.
Key Points:
- BET inhibitors demonstrate efficacy beyond hematologic cancers, showing potential in solid tumors.
- Understanding BET protein function is crucial for overcoming resistance to current cancer treatments.
- Ongoing clinical trials are exploring novel strategies and combinations involving BET inhibitors.
Conclusions:
- BET inhibitors represent a promising therapeutic strategy for a range of solid tumors.
- Further research into resistance mechanisms and toxicity profiles is essential for optimizing clinical use.
- Future applications of BET inhibitors may expand to include combination therapies and personalized treatment approaches.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:57Targeted Cancer Therapies
1.7K
1.7K
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K